Graft Versus Host Disease Market Size (7MM) is expected to grow from USD 1,626 million in 2025 to USD 3,304 million in 2034, estimates DelveInsight

DelveInsight's "Graft Versus Host Disease Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Graft Versus Host Disease, historical and forecasted epidemiology and the Graft Versus Host Disease market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore the intricate details of the Graft Versus Host Disease Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Graft Versus Host Disease Market Forecast- https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Graft Versus Host Disease Market Report
• On 14 November 2025, H. Lee Moffitt Cancer Center and Research Institute announced a Phase II study of Ruxolitinib vs Prednisone as First-Line Therapy for Chronic Graft vs Host Disease Needing Systemic Therapy.
• On 13 November 2025, Deciphera Pharmaceuticals, LLC conducted a study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.
• DelveInsight's epidemiology model estimates that in 2023, there were approximately 57 thousand allogenic transplant cases and nearly 52 thousand cases of Graft Versus Host Disease across the 7MM which are expected to increase by 2034.
• In 2023, the US reported the highest number of Graft Versus Host Disease cases among the 7MM, with approximately 24 thousand, a figure expected to rise by 2034.
• In 2023, Germany reported the highest number of Graft Versus Host Disease cases among EU4 and the UK, with approximately 8 thousand cases, followed by Italy and France, with around 3 thousand cases each. Spain had the lowest number, with approximately 27 hundred cases.
• In 2023, Japan reported approximately 8 thousand Graft Versus Host Disease cases, a number projected to increase by 2034.
• In 2023, the US reported around 5 thousand cases of Graft Versus Host Disease and approximately 18 thousand prevalent cases of Graft Versus Host Disease over five years.
• In 2023, EU4 and the UK reported the following distribution of Graft Versus Host Disease cases by grading: around 2 thousand cases of Grade B[II] Graft Versus Host Disease, approximately 1 thousand cases of Grade C[III] Graft Versus Host Disease, and approximately 8 hundred cases of Grade D[IV] Graft Versus Host Disease.
• In 2023, Germany reported approximately 9 hundred Graft Versus Host Disease cases involving the skin, approximately 4 hundred cases involving the liver, and approximately 8 hundred cases involving the gastrointestinal tract.
• The UK reported approximately 6 hundred mild, approximately 1 thousand moderate, and approximately 8 hundred severe cases of Graft Versus Host Disease by grading in 2023.
• In 2023, Japan reported the following Graft Versus Host Disease cases: around 1 thousand cases involving the skin, approximately 3 thousand cases affecting the oral mucosa, approximately 2 thousand cases impacting the eyes, around 3 hundred cases involving the liver,approximately 8 hundred cases in the gastrointestinal tract, around 2 thousand cases affecting the lungs, approximately 3 hundred cases involving the genitals, and approximately 4 hundred cases related to the joints and fascia.
• The leading Graft-Versus-Host Disease Companies such as CSL Behring, Equillium, Biocon, MaaT Pharma, Regimmune, Jazz Pharmaceuticals, Pharmacyclics LLC., Novartis, Biogen, Mallinckrodt, Astellas Pharma, Mesoblast, Inc., Thrasher Research Fund, Regimmune Corporation, Syndax Pharmaceutical, Novartis, and others.
• Promising Graft-Versus-Host Disease Therapies such as ZEMAIRA (CSL 964, alpha-1 antitrypsin), EQ001 (itolizumab; Bmab600), MaaT013, RGI-2001, Defibrotide, Ibrutinib, Panobinostat (LBH589), Natalizumab, Methoxsalen, Prograf, Prochymal®, Abatacept, RGI-2001, Axatilimab, Ruxolitinib, and others.

Navigate the complexities of the Graft Versus Host Disease Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Graft Versus Host Disease Market Forecast. Click here to get more insights @ https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Graft-Versus-Host Disease Epidemiology Segmentation in the 7MM
• Total Prevalence of Graft-Versus-Host Disease
• Prevalent Cases of Graft-Versus-Host Disease by severity
• Gender-specific Prevalence of Graft-Versus-Host Disease
• Diagnosed Cases of Episodic and Chronic Graft-Versus-Host Disease

Download the report to understand which factors are driving Graft-Versus-Host Disease epidemiology trends @ https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Graft Versus Host Disease Marketed Drugs

• JAKAFI MOA/JAKAVI (ruxolitinib): Incyte
JAKAFI MOA/JAKAVI (ruxolitinib) is a potent dual JAK1 and JAK2 inhibitor that exhibits low single-digit nanomolar biochemical IC50s for both kinases. The selectivity within the JAK family members is represented by a six-fold selectivity over TYK2 and approximately 130-fold selectivity over JAK3. Ruxolitinib demonstrates dose-dependent inhibition of JAK2/STAT signaling and inhibition of cell growth that is dependent on JAK2 activation.

• IMBRUVICA (ibrutinib): Pharmacyclics (acquired by AbbVie)/ Janssen
IMBRUVICA (ibrutinib) is a first-in-class, oral, once-daily therapy that inhibits a protein called Bruton's tyrosine kinase (BTK). BTK is a key signaling molecule in the B-cell receptor signaling complex that plays an important role in the survival and spread of malignant B cells and other serious, debilitating conditions. IMBRUVICA blocks signals that tell malignant B cells to multiply and spread uncontrollably.

Graft Versus Host Disease Emerging Drugs
• ZEMAIRA (CSL 964, alpha-1 antitrypsin): CSL Behring
CSL 964 is an Alpha1-proteinase Inhibitor (A1-PI) being developed by CSL Behring to treat steroid-refractory a Graft Versus Host Disease and prevent a Graft Versus Host Disease in high-risk patients receiving an allogeneic HSCT. ZEMAIRA is approved to treat chronic augmentation and maintenance therapy in adults with alpha1-proteinase inhibitors. ZEMAIRA acts as augmentation therapy for increasing and maintaining serum levels and the levels of lung Epithelial Lining Fluid (ELF) of A1-PI. The drug is currently in Phase III trials for treating steroid-refractory a Graft Versus Host Disease and in Phase II/III trials for preventing a Graft Versus Host Disease

• EQ001 (itolizumab; Bmab600): Equillium/Biocon
EQ001 (Itolizumab; Bmab600) is a first-in-class immune-modulating antibody designed to inhibit CD6 to reduce the activation and trafficking of pathogenic T cells that release pro-inflammatory cytokines of autoimmune and inflammatory diseases like Graft Versus Host Disease, uncontrolled moderate-to-severe asthma, and lupus nephritis. Itolizumab targets the CD6-ALCAM signaling pathway to selectively downregulate pathogenic effector T cells (Teffs) while preserving Tregs critical for maintaining a balanced immune response.

Unlock insights into the Graft Versus Host Disease Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Graft Versus Host Disease Market Forecast @ https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Graft-Versus-Host Disease Therapies and Companies
• JAKAFI MOA/JAKAVI (ruxolitinib): Incyte
• IMBRUVICA (ibrutinib): Pharmacyclics (acquired by AbbVie)/ Janssen
• ZEMAIRA (CSL 964, alpha-1 antitrypsin): CSL Behring
• EQ001 (itolizumab; Bmab600): Equillium/Biocon
• CSL 964 AAT (zemaira): CSL Behring
• MaaT013: MaaT Pharma
• RGI-2001: Regimmune
• Defibrotide: Jazz Pharmaceuticals
• Ibrutinib: Pharmacyclics LLC.
• Panobinostat (LBH589): Novartis
• Natalizumab: Biogen
• Methoxsalen: Mallinckrodt
• Prograf: Astellas Pharma
• Prochymal®: Mesoblast, Inc.
• Abatacept: Thrasher Research Fund
• RGI-2001: Regimmune Corporation
• Axatilimab: Syndax Pharmaceutical
• Ruxolitinib: Novartis

Graft-Versus-Host Disease Market Strengths
• Pipeline of GvHD is very robust and several late stage assets are expected to enter in to the market very soon. GvHD pipeline consists of small molecules, monoclonal and Bi-specific antibody, stem cell therapy, recombinant fusion protein etc. which will provide the patients and physicians more options in future.

Graft-Versus-Host Disease Market Opportunities
• Several upcoming therapies have received Orphan designations, therapies can get accelerated approval time, 7 years of market exclusivity in the US, clinical trials subsidies and reduced regulatory fees and others. Company can also go for premium pricing as well.

Gain a strategic edge in the Graft-Versus-Host Disease Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Graft-Versus-Host Disease Market Forecast. Click here to lead in advancements @ https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Graft-Versus-Host Disease Companies
CSL Behring, Equillium, Biocon, MaaT Pharma, Regimmune, Jazz Pharmaceuticals, Pharmacyclics LLC., Novartis, Biogen, Mallinckrodt, Astellas Pharma, Mesoblast, Inc., Thrasher Research Fund, Regimmune Corporation, Syndax Pharmaceutical, Novartis, and others.

Scope of the Graft Versus Host Disease Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Graft-Versus-Host Disease Companies- CSL Behring, Equillium, Biocon, MaaT Pharma, Regimmune, Jazz Pharmaceuticals, Pharmacyclics LLC., Novartis, Biogen, Mallinckrodt, Astellas Pharma, Mesoblast, Inc., Thrasher Research Fund, Regimmune Corporation, Syndax Pharmaceutical, Novartis, and others.
• Graft-Versus-Host Disease Therapies- ZEMAIRA (CSL 964, alpha-1 antitrypsin), EQ001 (itolizumab; Bmab600), MaaT013, RGI-2001, Defibrotide, Ibrutinib, Panobinostat (LBH589), Natalizumab, Methoxsalen, Prograf, Prochymal®, Abatacept, RGI-2001, Axatilimab, Ruxolitinib, and others.
• Graft-Versus-Host Disease Therapeutic Assessment: Graft-Versus-Host Disease current marketed and Graft-Versus-Host Disease emerging therapies
• Graft-Versus-Host Disease Market Dynamics: Graft-Versus-Host Disease market drivers and Graft-Versus-Host Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Graft-Versus-Host Disease Unmet Needs, KOL's views, Analyst's views, Graft-Versus-Host Disease Market Access and Reimbursement

To know more about Graft-Versus-Host Disease companies working in the treatment market, visit @ Graft-Versus-Host Disease Clinical Trials and Therapeutic Assessment- https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Graft-Versus-Host Disease Market Report Introduction
2. Executive Summary for Graft-Versus-Host Disease
3. SWOT analysis of Graft-Versus-Host Disease
4. Graft-Versus-Host Disease Patient Share (%) Overview at a Glance
5. Graft-Versus-Host Disease Market Overview at a Glance
6. Graft-Versus-Host Disease Disease Background and Overview
7. Graft-Versus-Host Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Graft-Versus-Host Disease
9. Graft-Versus-Host Disease Current Treatment and Medical Practices
10. Graft-Versus-Host Disease Unmet Needs
11. Graft-Versus-Host Disease Emerging Therapies
12. Graft-Versus-Host Disease Market Outlook
13. Country-Wise Graft-Versus-Host Disease Market Analysis (2020-2034)
14. Graft-Versus-Host Disease Market Access and Reimbursement of Therapies
15. Graft-Versus-Host Disease Market Drivers
16. Graft-Versus-Host Disease Market Barriers
17. Graft-Versus-Host Disease Appendix
18. Graft-Versus-Host Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.